TOP2A and neoplasm: MYBL2 is known to promote cell proliferation and EMT in many tumor types (Jin et al., 2017; Liang et al., 2017; Tao et al., 2015), and TOP2A is associated with worse prognosis in non‐small‐cell lung cancer patients (Hou et al., 2017).